These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8723496)

  • 1. Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.
    Wood PJ; Ioannides-Demos LL; Bastone EB; Spicer WJ; McLean AJ
    Antimicrob Agents Chemother; 1996 May; 40(5):1321-4. PubMed ID: 8723496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.
    Ioannides-Demos LL; Liolios L; Wood P; Spicer WJ; McLean AJ
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1365-9. PubMed ID: 9624477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.
    Zhu ZY; Li RC
    J Antimicrob Chemother; 1998 Jul; 42(1):61-5. PubMed ID: 9700529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.
    Li RC; Zhu ZY; Lee SW; Raymond K; Ling JM; Cheng AF
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1808-11. PubMed ID: 9257767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
    den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
    Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
    Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.
    den Hollander JG; Mouton JW; van Goor MP; Vleggaar FP; Verbrugh HA
    Antimicrob Agents Chemother; 1996 Mar; 40(3):784-6. PubMed ID: 8851612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval.
    den Hollander JG; Fuursted K; Verbrugh HA; Mouton JW
    Antimicrob Agents Chemother; 1998 Apr; 42(4):749-54. PubMed ID: 9559777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing.
    Bastone EB; Li SC; Ioannides-Demos LL; Spicer WJ; McLean AJ
    Antimicrob Agents Chemother; 1993 Apr; 37(4):914-7. PubMed ID: 8494392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing
    Müsken M; Pawar V; Schwebs T; Bähre H; Felgner S; Weiss S; Häussler S
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin.
    Martha B; Croisier D; Durand D; Hocquet D; Plesiat P; Piroth L; Portier H; Chavanet P
    Clin Microbiol Infect; 2006 May; 12(5):426-32. PubMed ID: 16643518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model.
    Cao B; Christophersen L; Thomsen K; Sønderholm M; Bjarnsholt T; Jensen PØ; Høiby N; Moser C
    J Antimicrob Chemother; 2015 Jul; 70(7):2057-63. PubMed ID: 25786481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.
    den Hollander JG; Mouton JW; Verbrugh HA
    Antimicrob Agents Chemother; 1998 Apr; 42(4):744-8. PubMed ID: 9559776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics.
    Li RC; Zhu ZY
    J Chemother; 2002 Dec; 14(6):579-83. PubMed ID: 12583549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.
    Rees VE; Bulitta JB; Oliver A; Tsuji BT; Rayner CR; Nation RL; Landersdorfer CB
    J Antimicrob Chemother; 2016 Nov; 71(11):3157-3167. PubMed ID: 27521357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa.
    Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC
    Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption.
    Loose M; Naber KG; Shields P; Reinhart H; Wagenlehner FME
    Int J Antimicrob Agents; 2018 Mar; 51(3):422-426. PubMed ID: 29158143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
    Canis F; Cavallo JD; Husson MO
    Pathol Biol (Paris); 1997 May; 45(5):420-3. PubMed ID: 9296096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.